Abstract Body

Background:

High levels of apolipoprotein E (apoE) in plasma are associated with increased risk of cardiovascular disease and all-cause mortality in the general population. APOE gene polymorphism accounts for 15-25% of variability in plasma apoE, but plasma apoE still vary between individuals with the same APOE genotype. Our aims were to assess if HIV is an independent risk factor for high plasma apoE and to determine HIV related risk factors for high plasma apoE.

Methods:

We included 661 people with HIV (PWH) frequency matched 1:1 on age and sex with uninfected controls from the general population. Only people of Danish ancestry were included to minimize differences in APOE genotypes. Both PWH and controls underwent physical examination, filled out extensive questionnaires and had blood samples drawn according to the same study protocol.High plasma apoE was defined as apoE levels above the 9th decile. The association between plasma apoE and HIV status was explored using both linear and logistic regression models adjusted for age, sex, body mass index, hypertension, diabetes, smoking, alcohol and plasma lipids. In PWH linear and logistic regression models were used to determine HIV-specific risk factors for high plasma apoE.

Results:

Mean age was 52 years and 11% were female in both groups. Median plasma apoE was 49.0 mg/L in PWH and 43.3 mg/L in controls. High apoE was defined as above 66.2 mg/L.In adjusted linear models PWH had 6.6 mg/L higher plasma apoE compared with controls [95%CI: 5.1 to 8.1 mg/L], p< 0.001. PWH also had higher odds of high plasma apoE with adjusted odds ratio (OR) of 2.55 [1.63, 3.99], p< 0.001. In age-adjusted analyses stratified by sex the estimated ORs for each sex were similar (OR 2.03 [1.35, 3.04], p< 0.001 for males and OR 2.02 [0.69, 5.89], p=0.20 for females).In PWH, previous AIDS defining disease was associated with 4.50 mg/L higher plasma apoE [1.52, 7.48 mg/L], p=0.003 in sex- and age-adjusted analysis. Previous AIDS was also associated with higher odds of high apoE (OR 1.78 [1.03, 3.06], p=0.04) in unadjusted analysis, but not in adjusted models. CD4 nadir, detectable viral load, and exposure to old generation anti-retroviral therapy was not associated with plasma apoE levels.

Conclusions:

PWH had higher concentrations of plasma apoE compared with uninfected controls even after adjusting for plasma lipids. Previous AIDS defining disease was associated with higher plasma apoE. Further studies are needed to elucidate the clinical impact of high plasma apoE in PWH.